Since joining IDRI in 2007, Dr. Fox has led development of cGMP vaccine adjuvant formulations for clinical evaluation of vaccine candidates against a variety of infectious diseases. He currently serves as principal investigator on NIH contracts to develop a first-in-human intranasal vaccine against amebiasis and to develop a thermostable tuberculosis vaccine through Phase 1 clinical testing. Moreover, he leads a BARDA-funded effort to establish a large-scale adjuvant manufacturing hub for pandemic influenza preparedness and an NIH R01 grant to develop sustainable raw material sources for vaccine adjuvant formulations using bioengineering and chemical engineering approaches. Dr. Fox has also directed technology transfer of adjuvant formulation manufacturing to institutes in India, Brazil, South Africa, and Romania. These local capacity building efforts were recognized in 2015 with the WGHA Pioneers of Global Health Rising Leader Award. Dr. Fox has authored >80 publications including serving as editor for the Springer Methods in Molecular Biology volume entitled “Vaccine Adjuvants: Methods and Protocols” published in 2017. Prior to joining IDRI, he obtained his Ph.D. in bioengineering at the University of Utah and his B.S. in biological engineering at Utah State University.